IGNT: AI 评分 49/100 — AI 分析 (4月 2026)

Ingen Technologies, Inc. specializes in manufacturing medical devices for the respiratory industry, particularly for patients with chronic obstructive pulmonary disease (COPD). Their key products include oxygen flow meters and nasal cannulas, marketed under the Oxyview and Smart Nasal Cannula trademarks.

Key Facts: AI Score: 49/100 Sector: Healthcare

公司概况

概要：

Ingen Technologies, Inc. manufactures and distributes respiratory medical devices, including oxygen flow meters and nasal cannulas, primarily serving patients with COPD. The company's focus on pneumatic metering devices and specialized nasal cannula technology positions it within a niche segment of the broader medical device market, characterized by increasing demand for home healthcare solutions.

IGNT是做什么的？

Founded in 1999 and based in Riverside, California, Ingen Technologies, Inc. operates as a medical device manufacturing company focused on the respiratory industry. The company develops, manufactures, and markets medical equipment designed for patients suffering from chronic obstructive pulmonary disease (COPD). Ingen's core product offerings include oxygen flow meters and nasal cannulas, marketed under the Oxyview and Smart Nasal Cannula trademarks. The Oxyview device is a pneumatic metering device that displays and confirms the oxygen flow rate near the patient, ensuring accurate and reliable oxygen delivery. The Smart Nasal Cannula is designed to enhance patient comfort and improve oxygen delivery efficiency. Ingen Technologies targets the home healthcare market, providing solutions that enable patients to manage their respiratory conditions effectively outside of a hospital setting. The company's focus on specialized respiratory devices differentiates it from larger medical device manufacturers with broader product portfolios. Ingen Technologies distributes its products primarily within the United States.

IGNT的投资论点是什么？

Ingen Technologies, Inc. presents a focused investment opportunity within the respiratory medical device sector. The company's specialization in oxygen flow meters and nasal cannulas for COPD patients positions it to capitalize on the growing demand for home healthcare solutions. A key value driver is the company's proprietary Oxyview technology, which offers precise oxygen flow monitoring. However, potential the may be worth researching company's negative P/E ratio of -0.05 and a significant negative profit margin of -7460.4%. While the gross margin is a high 95.7%, profitability remains a concern. Growth catalysts include expanding distribution networks and potential partnerships to reach a broader patient base. The investment thesis hinges on Ingen's ability to achieve profitability through increased sales volume and efficient cost management.

IGNT在哪个行业运营？

Ingen Technologies operates within the medical device industry, specifically targeting the respiratory care segment. This segment is driven by the increasing prevalence of respiratory diseases such as COPD, and the growing demand for home healthcare solutions. The market is competitive, with established players like AFIB (Acutus Medical, Inc.) and ALST (Allstar Healthcare, Inc.) offering a range of respiratory devices. Ingen Technologies differentiates itself through its focus on specialized oxygen delivery and monitoring devices. The industry is subject to regulatory oversight, requiring companies to obtain approvals for their products. Market trends include the adoption of telehealth and remote patient monitoring, which could create opportunities for Ingen Technologies to integrate its devices with digital health platforms.

Medical - Devices

Healthcare

IGNT有哪些增长机遇？

Expansion of Product Line: Ingen Technologies can expand its product line to include additional respiratory devices and accessories, such as nebulizers, ventilators, and sleep apnea devices. This would allow the company to cater to a broader range of respiratory conditions and increase its market share. The global market for respiratory devices is projected to reach $35 billion by 2028, providing a significant opportunity for growth. Timeline: 2-3 years.
Strategic Partnerships: Ingen Technologies can form strategic partnerships with home healthcare providers, hospitals, and durable medical equipment (DME) suppliers to expand its distribution network and reach a larger patient base. These partnerships can provide access to established sales channels and enhance the company's brand recognition. The market for home healthcare services is expected to grow at a rate of 8% annually, creating a favorable environment for partnerships. Timeline: 1-2 years.
Geographic Expansion: Ingen Technologies can expand its geographic presence beyond the United States to international markets, such as Europe and Asia, where there is a growing demand for respiratory care products. This would require obtaining regulatory approvals in each target market and establishing distribution channels. The global market for respiratory devices is expected to grow at a CAGR of 6% over the next five years, driven by increasing healthcare spending in emerging markets. Timeline: 3-5 years.
Telehealth Integration: Ingen Technologies can integrate its devices with telehealth platforms to enable remote patient monitoring and management. This would allow healthcare providers to track patients' oxygen levels and respiratory function remotely, improving patient outcomes and reducing healthcare costs. The telehealth market is projected to reach $175 billion by 2026, creating a significant opportunity for Ingen Technologies to leverage its technology. Timeline: 1-2 years.
Focus on Innovation: Ingen Technologies can invest in research and development to develop innovative respiratory devices and technologies that address unmet needs in the market. This could include developing more advanced oxygen delivery systems, wearable respiratory sensors, and AI-powered respiratory monitoring tools. The market for innovative medical devices is growing rapidly, driven by increasing demand for personalized and data-driven healthcare solutions. Timeline: Ongoing.

Ingen Technologies operates in the medical device industry, focusing on respiratory care products.
The company's primary products include oxygen flow meters and nasal cannulas under the Oxyview and Smart Nasal Cannula trademarks.
Ingen Technologies has a high gross margin of 95.7%, indicating efficient production processes.
The company's P/E ratio is -0.05, reflecting current losses.
Ingen Technologies serves patients suffering from chronic obstructive pulmonary disease (COPD).

IGNT提供哪些产品和服务？

Manufactures medical devices for the respiratory industry.
Produces medical equipment for patients with chronic obstructive pulmonary disease (COPD).
Offers oxygen flow meters under the Oxyview trademark.
Provides nasal cannulas under the Smart Nasal Cannula trademark.
Develops pneumatic metering devices to display and confirm oxygen flow rates.
Focuses on improving oxygen delivery and patient comfort.

IGNT如何赚钱？

Manufactures and sells oxygen flow meters and nasal cannulas.
Targets patients with chronic obstructive pulmonary disease (COPD).
Distributes products through medical equipment suppliers and healthcare providers.
Generates revenue from the sale of its medical devices.

Patients suffering from chronic obstructive pulmonary disease (COPD).
Hospitals and clinics providing respiratory care.
Home healthcare providers.
Durable medical equipment (DME) suppliers.

Specialized product line focused on respiratory care.
Proprietary Oxyview technology for accurate oxygen flow monitoring.
Established presence in the respiratory medical device market.
Brand recognition for Oxyview and Smart Nasal Cannula products.

什么因素可能推动IGNT股价上涨？

Upcoming: Potential partnerships with home healthcare providers to expand distribution.
Upcoming: Development and launch of new respiratory devices.
Ongoing: Increasing demand for home healthcare solutions for COPD patients.
Ongoing: Expansion of the Oxyview product line.
Ongoing: Integration of devices with telehealth platforms.

IGNT的主要风险是什么？

Potential: Competition from larger medical device manufacturers.
Potential: Regulatory changes affecting the medical device industry.
Ongoing: Economic downturn impacting healthcare spending.
Potential: Technological advancements rendering existing products obsolete.
Ongoing: The company's negative P/E ratio and high negative profit margin.

IGNT的核心优势是什么？

Specialized product line focused on respiratory care.
Proprietary Oxyview technology for accurate oxygen flow monitoring.
Established presence in the respiratory medical device market.
High gross margin of 95.7%.

IGNT的劣势是什么？

Negative P/E ratio of -0.05, indicating current losses.
High negative profit margin of -7460.4%.
Limited product diversification.
Dependence on the respiratory care market.

IGNT有哪些机遇？

Expansion of product line to include additional respiratory devices.
Strategic partnerships with home healthcare providers and DME suppliers.
Geographic expansion to international markets.
Integration of devices with telehealth platforms.

IGNT面临哪些威胁？

Competition from larger medical device manufacturers.
Regulatory changes affecting the medical device industry.
Economic downturn impacting healthcare spending.
Technological advancements rendering existing products obsolete.

IGNT的竞争对手是谁？

Acutus Medical, Inc. — Focuses on cardiac arrhythmia solutions. — (AFIB)
Allstar Healthcare, Inc. — Offers a broad range of healthcare products and services. — (ALST)
Aridis Pharmaceuticals, Inc. — Develops novel anti-infective therapies. — (ARDS)
China Green Healthcare Corp. — Operates in the healthcare sector in China. — (CGHC)
Infinity Q Volatility Alpha Fund — Investment fund focused on volatility strategies. — (INFIQ)

Key Metrics

MoonshotScore: 49/100

Company Profile

CEO: David S. Hanson
Headquarters: Riverside, US
Founded: 2009

AI Insight

AI analysis pending for IGNT

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Ingen Technologies, Inc. do?

Ingen Technologies, Inc. is a medical device manufacturing company specializing in respiratory care products. It primarily manufactures and markets oxygen flow meters under the Oxyview trademark and nasal cannulas under the Smart Nasal Cannula trademark. These devices are designed for patients suffering from chronic obstructive pulmonary disease (COPD), providing solutions for accurate oxygen delivery and patient comfort. The company focuses on serving the home healthcare market, enabling patients to manage their respiratory conditions effectively outside of a hospital setting. Ingen Technologies aims to improve the quality of life for COPD patients through its specialized respiratory devices.

What do analysts say about IGNT stock?

As of 2026-03-17, there is no available analyst coverage for Ingen Technologies, Inc. (IGNT). Given the company's OTC listing and small market capitalization, it is not widely followed by analysts. Key valuation metrics include a negative P/E ratio of -0.05 and a high gross margin of 95.7%. Growth considerations include the company's ability to expand its product line, form strategic partnerships, and penetrate international markets. Investors should conduct their own due diligence and consider the risks associated with investing in OTC-listed companies.

What are the main risks for IGNT?

The main risks for Ingen Technologies, Inc. include competition from larger medical device manufacturers, regulatory changes affecting the medical device industry, and the potential for an economic downturn impacting healthcare spending. The company's negative P/E ratio and high negative profit margin also pose significant risks. Additionally, technological advancements could render existing products obsolete. As an OTC-listed company, Ingen Technologies faces risks related to limited financial disclosure, low liquidity, and potential regulatory scrutiny. Investors should carefully consider these risks before investing in IGNT.